Get the Stockscreener App
1.62
1.22%
-0.02
After Hours:
1.63
0.010
+0.62%
20 20 Biolabs Inc stock is traded at $1.62, with a volume of 241.07K.
It is down -1.22% in the last 24 hours and down -71.48% over the past month.
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.
See More
Previous Close:
$1.64
Open:
$1.64
24h Volume:
241.07K
Relative Volume:
1.48
Market Cap:
$16.76M
Revenue:
$1.65M
Net Income/Loss:
$-5.66M
P/E Ratio:
-1.3729
EPS:
-1.18
Net Cash Flow:
-
1W Performance:
-18.18%
1M Performance:
-71.48%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$1.6001
$1.79
1-Week Range:
$1.51
$2.191
52-Week Range:
$1.51
$14.09
20 20 Biolabs Inc Stock (AIDX) Company Profile
Compare AIDX vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AIDX
20 20 Biolabs Inc
|
1.62 | 16.97M | 1.65M | -5.66M | 0 | -1.18 |
ABT
Abbott Laboratories
|
104.83 | 180.82B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
327.65 | 125.72B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
87.89 | 111.16B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
69.78 | 101.28B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
82.67 | 47.45B | 6.07B | 1.06B | 1.34B | 1.8063 |
20 20 Biolabs Inc Stock (AIDX) Latest News
20/20 BioLabs licenses kidney disease prediction technology from ROKIT Healthcare - MSN
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
20/20 BioLabs enters exclusive technology license, access agreement with Rokit - TipRanks
What's Going On With 20/20 Biolabs Stock? - Benzinga
20/20 Biolabs Faces Decline Amid Market Rut - timothysykes.com
20/20 BioLabs licenses kidney disease prediction technology - Investing.com
20/20 BioLabs Announces Exclusive U.S. License Agreement with ROKIT Healthcare to Integrate Advanced CKD Prediction Technology into Its Longevity Test Program - The Manila Times
Kidney disease risk check joins 20/20 BioLabs longevity test - Stock Titan
What is the current Price Target and Forecast for 20/20 Biolabs Inc. (AIDX) - Zacks Investment Research
What date does 20/20 Biolabs Inc.'s (AIDX) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
AIDX Stock Price, News & Analysis - Stock Titan
Debt to equity ratio of 20/20 Biolabs, Inc. – NASDAQ:AIDX - TradingView
AIDX: 20/20 Biolabs Inc.Options Chain - Zacks Investment Research
20/20 Biolabs Inc. (AIDX) Total Long Term Debt (Quarterly) - Zacks Investment Research
20/20 Biolabs Inc. (AIDX) Return On Assets (TTM) - Zacks Investment Research
20/20 Biolabs Inc. (AIDX) Total Expenses (TTM) - Zacks Investment Research
20/20 Biolabs Inc. (AIDX) Price Book Value - Zacks Investment Research
Cash per share of 20/20 Biolabs, Inc. – NASDAQ:AIDX - TradingView
Michael A. Ross Net Worth (2026) - GuruFocus
Michael Saul Lebowitz Net Worth (2026) - GuruFocus
Jonathan M Cohen Net Worth (2026) - GuruFocus
Prasanth Reddy Net Worth (2026) - GuruFocus
Jiming Zhou Net Worth (2026) - GuruFocus
20/20 BioLabs Highlights Advantages of its Patented Protein Biomarker Technology for Multi-Cancer Early Detection in Light of Recent Studies - Sahm
20/20 Biolabs, Inc. Revenue Breakdown – NASDAQ:AIDX - TradingView
Analysts Offer Insights on Healthcare Companies: 20/20 Biolabs, Inc. (AIDX) and Biogen (BIIB) - The Globe and Mail
20/20 BioLabs provides update on protein biomarket technology for MCED - TipRanks
Jonathan Cohen Discloses Investment at 20/20 Biolabs with 16.8% Stake - TradingView
20/20 Biolabs (NASDAQ: AIDX) CEO holds 16.8% stake in company - Stock Titan
20/20 Biolabs (AIDX) CEO awarded 352,936-share stock option grant - Stock Titan
20/20 Biolabs Inc. (AIDX) Revenue (Quarterly) Yoy Growth - Zacks Investment Research
20/20 Biolabs (AIDX) 10K Form and SEC Filings 2026 - MarketBeat
20/20 Biolabs Inc. (AIDX) Free Cash Flow (TTM) - Zacks Investment Research
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
20/20 Biolabs Inc. (AIDX) Price To Cash Flow - Zacks Investment Research
20/20 Biolabs Inc. (AIDX) Net Income (Quarterly) - Zacks Investment Research
AIDX News Today | Why did 20/20 Biolabs stock go down today? - MarketBeat
20/20 Biolabs (AIDX) Stock Price, News & Analysis - MarketBeat
20/20 Biolabs Inc. (AIDX) Cash From Operations (TTM) - Zacks Investment Research
Number of employees of 20/20 Biolabs, Inc. – NASDAQ:AIDX - TradingView
20/20 Biolabs Inc. (AIDX) Cash From Financing (TTM) - Zacks Investment Research
20/20 Biolabs Inc. (AIDX) Dividend Yield (TTM) - Zacks Investment Research
20/20 Biolabs Inc. (AIDX) Shareholders Equity (Quarterly) - Zacks Investment Research
20/20 Biolabs Inc. (AIDX) Revenue (Quarterly) - Zacks Investment Research
20/20 Biolabs Inc. (AIDX) Profit Margin (Quarterly) - Zacks Investment Research
20/20 Biolabs Inc. (AIDX) Revenue (TTM) - Zacks Investment Research
20/20 Biolabs Inc. (AIDX) - Zacks Investment Research
20/20 Biolabs Inc. (AIDX) Total Assets (Quarterly) - Zacks Investment Research
20/20 Biolabs Inc. (AIDX) Ps Ratio (TTM) - Zacks Investment Research
20/20 Biolabs, Inc. Common Stock (AIDX) Competitors - Meyka
20/20 Biolabs, Inc. Common Stock (AIDX) AI-Powered Stock Analysis - Meyka
20 20 Biolabs Inc Stock (AIDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):